Business description
Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and biomaterials for use in tooth replacement and restoration solutions or to prevent tooth loss.
Management board & Supervisory board
| CEO |
| Guillaume Daniellot |
| Management board |
| Dr. Peter Hackel, Alastair Robertson, Aurelio Sahagun, Camila Finzi, Christian Ullrich, Dirk Reznik, Holger Haderer, Mark Johnson, Matthias Schupp, Patrick Kok-Kien Loh, Rahma Samow, Wolfgang Becker |
| Supervisory board |
| Gilbert Achermann, Dr. Beat Lüthi, Dr. Thomas Straumann, Juan-José Gonzalez, Marco Gadola, Nadia Tarolli Schmidt, Petra Rumpf, Regula Wallimann |
Company data
| Name: |
Straumann Holding AG |
| Address: |
Peter Merian-Weg 12,CH-4052 Basel |
| Phone: |
+41-61-965-1111 |
| Fax: |
+41-61-965-1101 |
| E-mail: |
info@straumann.com
|
| Internet: |
www.straumann.com |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Advanced Medical Devices |
| End of financial year: |
12/31 |
| Free Float: |
57.90% |
| IPO date: |
- |